Association of baseline microbiome and responders to immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT).
Melissa Lauren Abel(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Katherine Lee-Wisdom(National Institutes of Health), Amy Hankin(National Institutes of Health), Esther Mena(National Institutes of Health), Monique Williams(National Institutes of Health), Clara Chen(National Institutes of Health), Fatima Karzai(National Institutes of Health), James L. Gulley(National Institutes of Health), Philip M. Arlen(National Institutes of Health), Jeanny B. Aragon-Ching(Virginia Cancer Institute), Richard R. Rodrigues(National Institutes of Health), Heidi Kong(National Institutes of Health), Peter L. Choyke(National Institutes of Health), William D. Figg(National Institutes of Health), Liza Lindenberg(National Institutes of Health), Elias Chandran(National Institutes of Health)
Cited by 0
Related Papers
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
|JNCI Journal of the National Cancer Institute|2006|345
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|327
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
|Journal for ImmunoTherapy of Cancer|2018|314
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
|Cancer Immunology Immunotherapy|2009|298